Rakuten Aspyrian has raised $150 million in a series C round to fund its photoimmunotherapy platform and a phase 3 trial in head and neck cancer, alongside plans to expand its pipeline to include other tumor types, both as a monotherapy and in combination with other cancer treatments.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,